Scotia Capital’s CRISPR Therapeutics CRSP Stock Holding History

Scotia Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,234	Closed	-$987K	–	906
2025 Q3	$987K	Sell	15,234 -278	-2%	-$16K	﹤0.01%	566
2025 Q2	$754K	Buy	15,512 +569	+4%	+$22K	﹤0.01%	569
2025 Q1	$509K	Buy	14,943 +2,648	+22%	+$112K	﹤0.01%	616
2024 Q4	$484K	Buy	12,295 +1,300	+12%	+$61.4K	﹤0.01%	628
2024 Q3	$517K	Buy	10,995 +40	+0.4%	+$2.03K	﹤0.01%	612
2024 Q2	$592K	Sell	10,955 -670	-6%	-$38.8K	﹤0.01%	581
2024 Q1	$792K	Buy	11,625 +545	+5%	+$39K	﹤0.01%	533
2023 Q4	$694K	Buy	11,080 +1,864	+20%	+$103K	﹤0.01%	525
2023 Q3	$418K	Sell	9,216 -412	-4%	-$21.3K	﹤0.01%	583
2023 Q2	$541K	Buy	+9,628	New	+$546K	﹤0.01%	542
2021 Q3	–	Sell	-1,399	Closed	-$226K	–	857
2021 Q2	$226K	Buy	+1,399	New	+$170K	﹤0.01%	761

Other funds holding CRSP

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital International Investors

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GSK plc London $599M AUM

UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return